Loading...
Blood and blood components
This is the fifth edition of CAN/CSA-Z902, Blood and blood components. It supersedes the previous editions published in 2020, 2015, 2010, and 2004. See Annex A for a list of major changes to this edition. CSA Group acknowledges that the development of this Standard was made possible, in part, by the financial support of Health Canada. This Standard was prepared by the Technical Committee on Blood and Blood Components, under the jurisdiction of the Strategic Steering Committee on Health and Well-being, and has been formally approved by the Technical Committee. This Standard has been developed in compliance with Standards Council of Canada requirements for National Standards of Canada. It has been published as a National Standard of Canada by CSA Group.
This Standard provides management requirements for facilities that collect, process, store, and use human blood components for transfusion. It addresses issues on safety, efficacy, and quality for recipients, safety of donors, management of blood components, and safety of facility personnel and others who are exposed to or potentially affected by blood components.
This Standard applies to blood centres, transfusion services, and any other organization that collects, processes, stores, or uses human blood components for transfusion.
It also includes requirements for the storage and use of blood products, when such products are within the responsibility of an organization that is covered by this Standard. Note: While this Standard does not specifically apply to organizations that manage blood products but not blood components (e.g., a hospital pharmacy), these organizations are encouraged to review the relevant requirements for blood products and incorporate them as appropriate into their procedures.
Operating procedures As a management standard, this Standard is not intended to replace detailed specifications and operating procedures; rather, it is intended for use in their preparation. It includes requirements for policies and procedures, quality management, personnel, physical plant, and equipment. In addition, this Standard outlines specific requirements to be included in the facility's operating procedures for the following activities
This Standard does not include requirements for activities associated with the
Note: Plasma for use in the manufacture of a drug for human use is covered under Blood Regulations
In this Standard, "shall" is used to express a requirement, i.e., a provision that the user is obliged to satisfy in order to comply with the Standard; "should" is used to express a recommendation or that which is advised but not required; and "may" is used to express an option or that which is permissible within the limits of the Standard. Notes accompanying clauses do not include requirements or alternative requirements; the purpose of a note accompanying a clause is to separate from the text explanatory or informative material. Notes to tables and figures are considered part of the table or figure and may be written as requirements. Annexes are designated normative (mandatory) or informative (non-mandatory) to define their application.
| SDO | CSA: Canadian Standards Association |
| Document Number | |
| Publication Date | Jan. 1, 2025 |
| Language | en - English |
| Page Count | 166 |
| Revision Level | |
| Supercedes | |
| Committee |
Failed to load document history.
| Publish Date | Document Id | Type | View |
|---|